call. everyone us today’s good to afternoon Thank and joining you, Robert, on
our globally trial. activities quarter at top clinical execute sites to X Phase this enrollment priority Our VIKTORIA-X for was continuing trial
CDKX/X with or in evaluating compound combined inhibitor. As gedatolisib we’ve a progressed cancer with patients fulvestrant, breast lead without with our advanced receiving disease whose previously, while is discussed palbociclib HR+/HERX- VIKTORIA-X
of fantastic possible. in team countries. recruiting pleased of done to to our sites begin a to the year, report we sites the and authorities focused the quickly for our this in keeping of XXXX. that with second trial has XX regulatory primary first coordinating the in Throughout patient are the analysis mutated individual as recruiting the subgroup relentlessly and XXX subgroup job us patient as the have ensure report in XXXX, patients now can PIKXCA They’re half primary for non-mutated nearly of patients first PIXK analysis half sites We half on track
This with is previously consistent discussed expectations. our
We’re over potential seeking on We of receives to line XXX,XXX outcomes from represents basis. standard limited therapies. improve current target cancer that care population breast patients population initial this that a second for annual globally patient benefit estimate an
in regimens the patients and an profile. standard specific targeted case Current periods, therapies combine only as mTOR of modest therapy. for a offer challenging approved with progression-free care fulvestrant such survival specific and inhibitor, PIXKα or that endocrine therapies these PIXKα includes These of very fulvestrant the safety
an X need subsequent with new unmet these patients significant mutation development positive its and SERD oral AKT recently was has aimed a cancer breast last study therapies patients to at patients. inhibitor for for ESRX from number of investigation year. An reported late results an The these of approved Phase significant led and
for to our X.X from in patient PFS new Median population. months therapies two X.X these ranged
will the always good While on reported unmet new still patients drugs, drug the alternatives availability for results for for remain. need of is these the news patients based these
these simultaneous strongly other. patients. activate is that consensus optimize this suggests Xb our these involves cancer three for which pathways, we’ve PIXK/mTOR of inhibition leading breast amongst Phase pathways disease, a we Most and outcomes data researchers estrogen required cross HR+/HERX- the the breast each can general believe treat effectively there’s As from previously, discussed to of cancer study that CDKX/X
drugs that a only modest that partial randomized pathway, provide AKT, And have single can of date such mTORCX patients prior as anti-tumor pathway component shown when treatment. PIXKα, that with consistently only or ones of target target PIXK/mTOR effects to studies have inhibition CDKX/X this on the progressed
of is address as this equipotent differentiated tumor. activity uniquely or action and an most Thus, a especially has PIXK/mTOR in effectively independent inhibitor the to we presence believe suited unmet gedatolisib mutations highly since of ESRX of gedatolisib PIKXCA mechanism demonstrated need, patient’s
median in ESMO Congress the and study. Our patients reported response. women our May patients months reinforced confidence HR+/HERX- survival updated play for in reported naïve important breast first-line improving breast PFS with obtained advanced XX% the period can an with gedatolisib data a cancer with progression-free of from Xb XX.X objective Breast advanced that letrozole palbociclib for Cancer Treatment with Phase was and role treated we gedatolisib, outcomes at HR+/HERX- cancer an
study for were for XX.X rate letrozole. reported suggests comparable and the the pathway. treatment without gedatolisib data the very to rationale for with selective the and mutations palbociclib PIKXCA highlighting XX% response We favorably a patients opposed as to of plus potential inhibition eventually Outcomes These PFS compare PALOMA-X become months to comprehensive the the PIXK/mTOR believe in results the median has of first-line objective option.
other and for in and hormonally gedatolisib. trials driven AKT, Last mTOR We tumor previous and new other for year, mTOR potential the we inhibitors gedatolisib of assessed inhibitors activity indications characterize began PIXK, PIXK different and types. prioritizing evaluating
GU at from in cancers results gynecological at presented prostate April. and in were ASCO AACR February in studies non-clinical in Our cancer initial
types In prior there develop exhibited on AKT, significant action the evaluated. AKT in provides, inhibitors mTOR believe PIXK, these us gedatolisib each additional activity the relative based over and of our inhibitors and to of to mechanism Thus tumor of studies time. assessment a opportunity for gedatolisib’s with advantage of is of we other superior review mTOR gedatolisib these PIXK, the clinical studies, all relative
quarter. We expect to the an provide development you end pipeline update on our by third with of the strategy
It to Now, cell on our CELsignia, business. like discussion third platform. our side diagnostic the diagnostics of I’d generation shift our to centers
CELsignia hyperactive HR+/HERX- stage patients early test. is breast Our ongoing with cancer, FACT-X our HERX and are whose pathway trials with and detected FACT-X enrolling as
announce first from in the results expect studies these continue of to interim We XXXX. half to
results. With call over our to now turn that, I’ll Vicky the Hahne to review financial
